Radionuclide and hybrid imaging of recurrent prostate cancer

The Lancet Oncology

Volumn 12, Issue 2, 2011, Pages 181-191

  Beer, Ambros J ^a   Eiber, Matthias ^a   Souvatzoglou, Michael ^a   Schwaiger, Markus ^a   Krause, Bernd Joachim ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 AMINO 3 FLUROCYCLOBUTYL 1CARBOXYLIC ACID F 18; 1 AMINO CYCLOBUTANE CARBOXYLIC ACID C 11; ACETIC ACID C 11; ANDROGEN RECEPTOR; ANDROSTANOLONE F 18; BOMBESIN TC 99M; BOMBESIN[3 LYSINE]FLUROBENZOATE F 18; CHOLINE C 11; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; FLUTAMIDE; GASTRIN RELEASING PEPTIDE RECEPTOR; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOISOTOPE; RP 527; RP 527 TC 99M; TECHNETIUM 99M; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

BONE METASTASIS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER RECURRENCE; CARCINOGENESIS; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; DRUG PROTEIN BINDING; DRUG UPTAKE; HUMAN; IMAGE ANALYSIS; INTERMETHOD COMPARISON; LYMPH NODE METASTASIS; LYMPHANGIOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; UPREGULATION;

HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NEOPLASM RECURRENCE, LOCAL; POSITRON-EMISSION TOMOGRAPHY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79151483760     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(10)70103-0     Document Type: Review

References (87)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. Beresford MJ, Gillatt D, Benson RJ, Ajithkumar T A systematic review of the role of imaging before salvage radiotherapy for post-prostatectomy biochemical recurrence. Clin Oncol 2010, 22:46-55.
3. Beyer T, Townsend DW, Brun T, et al. A combined PET/CT scanner for clinical oncology. J Nucl Med 2000, 41:1369-1379.
4. Buck AK, Nekolla S, Ziegler S, et al. SPECT/CT. J Nucl Med 2008, 49:1305-1319.
5. Nunez R, Macapinlac HA, Yeung HW, et al. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med 2002, 43:46-55.
6. Schoder H, Herrmann K, Gonen M, et al. 2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res 2005, 11:4761-4769.
7. Dehdashti F, Picus J, Michalski JM, et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma. Eur J Nucl Med Mol Imaging 2005, 32:344-350.
8. Larson SM, Morris M, Gunther I, et al. Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer. J Nucl Med 2004, 45:366-373.
9. Wachter S, Tomek S, Kurtaran A, et al. 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer. J Clin Oncol 2006, 24:2513-2519.
10. Hara T, Kosaka N, Kishi H PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998, 39:990-995.
11. Hara T, Kosaka N, Kishi H Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging. J Nucl Med 2002, 43:187-199.
12. DeGrado TR, Coleman RE, Wang S, et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001, 61:110-117.
13. de Molina A Ramirez, Rodriguez-Gonzalez A, Gutierrez R, et al. Overexpression of choline kinase is a frequent feature in human tumor-derived cell lines and in lung, prostate, and colorectal human cancers. Biochem Biophys Res Commun 2002, 296:580-583.
14. Katz-Brull R, Degani H Kinetics of choline transport and phosphorylation in human breast cancer cells; NMR application of the zero trans method. Anticancer Res 1996, 16:1375-1380.
15. Hara T, Bansal A, DeGrado TR Choline transporter as a novel target for molecular imaging of cancer. Mol Imaging 2006, 5:498-509.
16. Castellucci P, Fuccio C, Nanni C, et al. Influence of trigger PSA and PSA kinetics on 11C-Choline PET/CT detection rate in patients with biochemical relapse after radical prostatectomy. J Nucl Med 2009, 50:1394-1400.
17. Cimitan M, Bortolus R, Morassut S, et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006, 33:1387-1398.
18. Husarik DB, Miralbell R, Dubs M, et al. Evaluation of [(18)F]-choline PET/CT for staging and restaging of prostate cancer. Eur J Nucl Med Mol Imaging 2008, 35:253-263.
19. Rinnab L, Simon J, Hautmann RE, et al. [(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy. World J Urol 2009, 27:619-625.
20. Schmid DT, John H, Zweifel R, et al. Fluorocholine PET/CT in patients with prostate cancer: initial experience. Radiology 2005, 235:623-628.
21. Vees H, Buchegger F, Albrecht S, et al. 18F-choline and/or 11C-acetate positron emission tomography: detection of residual or progressive subclinical disease at very low prostate-specific antigen values (<1 ng/mL) after radical prostatectomy. BJU Int 2007, 99:1415-1420.
22. Breeuwsma AJ, Pruim J, van den Bergh AC, et al. Detection of local, regional, and distant recurrence in patients with PSA relapse after external-beam radiotherapy using (11)C-choline positron emission tomography. Int J Radiat Oncol Biol Phys 2010, 77:160-164.
23. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003, 44:32-38.
24. Picchio M, Messa C, Landoni C, et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003, 169:1337-1340.
25. Rinnab L, Mottaghy FM, Blumstein NM, et al. Evaluation of [11C]-choline positron-emission/computed tomography in patients with increasing prostate-specific antigen levels after primary treatment for prostate cancer. BJU Int 2007, 100:786-793.
26. Scattoni V, Picchio M, Suardi N, et al. Detection of lymph-node metastases with integrated [11C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic-retroperitoneal lymphadenectomy. Eur Urol 2007, 52:423-429.
27. Reske SN, Blumstein NM, Glatting G [11C]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy. Eur J Nucl Med Mol Imaging 2008, 35:9-17.
28. Krause BJ, Souvatzoglou M, Tuncel M, et al. The detection rate of [11C]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer. Eur J Nucl Med Mol Imaging 2008, 35:18-23.
29. Heinisch M, Dirisamer A, Loidl W, et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA <5 ng/ml?. Mol Imaging Biol 2006, 8:43-48.
30. Giovacchini G, Picchio M, Coradeschi E, et al. Predictive factors of [(11)C]choline PET/CT in patients with biochemical failure after radical prostatectomy. Eur J Nucl Med Mol Imaging 2010, 37:301-309.
31. Blau M, Nagler W, Bender MA Fluorine-18: a new isotope for bone scanning. J Nucl Med 1962, 3:332-334.
32. Even-Sapir E, Mishani E, Flusser G, Metser U 18F-Fluoride positron emission tomography and positron emission tomography/computed tomography. Semin Nucl Med 2007, 37:462-469.
33. Schirrmeister H, Guhlmann A, Elsner K, et al. Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET. J Nucl Med 1999, 40:1623-1629.
34. Even-Sapir E, Metser U, Flusser G, et al. Assessment of malignant skeletal disease: initial experience with 18F-fluoride PET/CT and comparison between 18F-fluoride PET and 18F-fluoride PET/CT. J Nucl Med 2004, 45:272-278.
35. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP planar bone scintigraphy, single- and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006, 47:287-297.
36. Beheshti M, Vali R, Waldenberger P, et al. Detection of bone metastases in patients with prostate cancer by 18F fluorocholine and 18F fluoride PET-CT: a comparative study. Eur J Nucl Med Mol Imaging 2008, 35:1766-1774.
37. Ghosh A, Heston WD Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer. J Cell Biochem 2004, 91:528-539.
38. Hinkle GH, Burgers JK, Neal CE, et al. Multicenter radioimmunoscintigraphic evaluation of patients with prostate carcinoma using indium-111 capromab pendetide. Cancer 1998, 83:739-747.
39. Manyak MJ Indium-111 capromab pendetide in the management of recurrent prostate cancer. Expert Rev Anticancer Ther 2008, 8:175-181.
40. Sodee DB, Malguria N, Faulhaber P, Resnick MI, Albert J, Bakale G Multicenter ProstaScint imaging findings in 2154 patients with prostate cancer. The ProstaScint Imaging Centers. Urology 2000, 56:988-993.
41. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997, 277:467-471.
42. O'Dowd GJ, Veltri RW, Orozco R, Miller MC, Oesterling JE Update on the appropriate staging evaluation for newly diagnosed prostate cancer. J Urol 1997, 158:687-698.
43. Krasnow AZ, Hellman RS, Timins ME, Collier BD, Anderson T, Isitman AT Diagnostic bone scanning in oncology. Semin Nucl Med 1997, 27:107-141.
44. Jacobson AF, Stomper PC, Cronin EB, Kaplan WD Bone scans with one or two new abnormalities in cancer patients with no known metastases: reliability of interpretation of initial correlative radiographs. Radiology 1990, 174:503-507.
45. Utsunomiya D, Shiraishi S, Imuta M, et al. Added value of SPECT/CT fusion in assessing suspected bone metastasis: comparison with scintigraphy alone and nonfused scintigraphy and CT. Radiology 2006, 238:264-271.
46. Horger M, Eschmann SM, Pfannenberg C, et al. Evaluation of combined transmission and emission tomography for classification of skeletal lesions. AJR Am J Roentgenol 2004, 183:655-661.
47. Romer W, Nomayr A, Uder M, Bautz W, Kuwert T SPECT-guided CT for evaluating foci of increased bone metabolism classified as indeterminate on SPECT in cancer patients. J Nucl Med 2006, 47:1102-1106.
48. Tuncel M, Souvatzoglou M, Herrmann K, et al. [(11)C]Choline positron emission tomography/computed tomography for staging and restaging of patients with advanced prostate cancer. Nucl Med Biol 2008, 35:689-695.
49. Scher HI, Sawyers CL Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 2005, 23:8253-8261.
50. Markwalder R, Reubi JC Gastrin-releasing peptide receptors in the human prostate: relation to neoplastic transformation. Cancer Res 1999, 59:1152-1159.
51. Nagalla SR, Barry BJ, Falick AM, et al. There are three distinct forms of bombesin. Identification of [Leu13]bombesin, [Phe13]bombesin, and [Ser3,Arg10,Phe13]bombesin in the frog Bombina orientalis. J Biol Chem 1996, 271:7731-7737.
52. Nock B, Nikolopoulou A, Chiotellis E, et al. [99mTc]Demobesin 1, a novel potent bombesin analogue for GRP receptor-targeted tumour imaging. Eur J Nucl Med Mol Imaging 2003, 30:247-258.
53. Chen X, Park R, Hou Y, et al. MicroPET and autoradiographic imaging of GRP receptor expression with 64Cu-DOTA-[Lys3]bombesin in human prostate adenocarcinoma xenografts. J Nucl Med 2004, 45:1390-1397.
54. Zhang X, Cai W, Cao F, et al. 18F-labeled bombesin analogs for targeting GRP receptor-expressing prostate cancer. J Nucl Med 2006, 47:492-501.
55. Van de Wiele C, Dumont F, Vanden Broecke R, et al. Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur J Nucl Med 2000, 27:1694-1699.
56. De Vincentis G, Remediani S, Varvarigou AD, et al. Role of 99mTc-bombesin scan in diagnosis and staging of prostate cancer. Cancer Biother Radiopharm 2004, 19:81-84.
57. Maecke HR, Hofmann M, Haberkorn U (68)Ga-labeled peptides in tumor imaging. J Nucl Med 2005, 46(suppl 1):172-178.
58. Apolo AB, Pandit-Taskar N, Morris MJ Novel tracers and their development for the imaging of metastatic prostate cancer. J Nucl Med 2008, 49:2031-2041.
59. Washburn LC, Sun TT, Byrd B, Hayes RL, Butler TA 1-aminocyclobutane[11C]carboxylic acid, a potential tumor-seeking agent. J Nucl Med 1979, 20:1055-1061.
60. Schuster DM, Votaw JR, Nieh PT, et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med 2007, 48:56-63.
61. Pandit-Taskar N, O'Donoghue JA, Morris MJ, et al. Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy. J Nucl Med 2008, 49:1066-1074.
62. Mease RC, Dusich CL, Foss CA, et al. N-[N-[(S)-1,3-Dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L-cysteine, [18F]DCFBC: a new imaging probe for prostate cancer. Clin Cancer Res 2008, 14:3036-3043.
63. Cooper CR, Chay CH, Pienta KJ The role of alpha(v)beta(3) in prostate cancer progression. Neoplasia 2002, 4:191-194.
64. Beekman KW, Colevas AD, Cooney K, et al. Phase II evaluations of cilengitide in asymptomatic patients with androgen-independent prostate cancer: scientific rationale and study design. Clin Genitourin Cancer 2006, 4:299-302.
65. Haubner R, Weber WA, Beer AJ, et al. Noninvasive visualization of the activated alphavbeta3 integrin in cancer patients by positron emission tomography and [18F]Galacto-RGD. PLoS Med 2005, 2:70.
66. Beer AJ, Grosu AL, Carlsen J, et al. [18F]galacto-RGD positron emission tomography for imaging of alphavbeta3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007, 13:6610-6616.
67. Liu Z, Li ZB, Cao Q, Liu S, Wang F, Chen X Small-animal PET of tumors with (64)Cu-labeled RGD-bombesin heterodimer. J Nucl Med 2009, 50:1168-1177.
68. Takeda M, Akiba H, Yama N, Hareyama M, Miyazak T Value of multi-sectional fast contrast-enhanced MR imaging in patients with elevated PSA levels after radical prostatectomy. Am J Roentgenol 2002, 178(suppl):97.
69. Eiber M, Krause BJ, Gschwend J, Schwaiger M, Beer AJ Comparison of whole-torso diffusion-weighted MRI and 11C-Choline PET/CT in recurrent prostate cancer patients. J Nucl Med Meeting Abstracts 2009, 50(suppl 2):63.
70. Chan TW, Kressel HY Prostate and seminal vesicles after irradiation: MR appearance. J Magn Reson Imaging 1991, 1:503-511.
71. Coakley FV, Hricak H, Wefer AE, Speight JL, Kurhanewicz J, Roach M Brachytherapy for prostate cancer: endorectal MR imaging of local treatment-related changes. Radiology 2001, 219:817-821.
72. Pucar D, Shukla-Dave A, Hricak H, et al. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience. Radiology 2005, 236:545-553.
73. Coakley FV, Teh HS, Qayyum A, et al. Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience. Radiology 2004, 233:441-448.
74. Menard C, Smith IC, Somorjai RL, et al. Magnetic resonance spectroscopy of the malignant prostate gland after radiotherapy: a histopathologic study of diagnostic validity. Int J Radiat Oncol Biol Phys 2001, 50:317-323.
75. Kim CK, Park BK, Lee HM Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI. J Magn Reson Imaging 2009, 29:391-397.
76. Haider MA, Chung P, Sweet J, et al. Dynamic contrast-enhanced magnetic resonance imaging for localization of recurrent prostate cancer after external beam radiotherapy. Int J Radiation Oncol Biol Physics 2008, 70:425-430.
77. Rouvière O, Valette O, Grivolat S, et al. Recurrent prostate cancer after external beam radiotherapy: value of contrast-enhanced dynamic MRI in localizing intraprostatic tumor-correlation with biopsy findings. Urology 2004, 63:922-927.
78. Heesakkers RA, Hovels AM, Jager GJ, et al. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study. Lancet Oncol 2008, 9:850-856.
79. Razek AA Abdel, Soliman NY, Elkhamary S, Alsharaway MK, Tawfik A Role of diffusion-weighted MR imaging in cervical lymphadenopathy. Eur Radiol 2006, 16:1468-1477.
80. Holzapfel K, Duetsch S, Fauser C, Eiber M, Rummeny EJ, Gaa J Value of diffusion-weighted MR imaging in the differentiation between benign and malignant cervical lymph nodes. Eur J Radiol 2008, 72:381-387.
81. Eiber M, Beer AJ, Holzapfel K, et al. Preliminary results for characterization of pelvic lymph nodes in patients with prostate cancer by diffusion-weighted MR-imaging. Invest Radiol 2010, 45:15-23.
82. Lecouvet FE, Geukens D, Stainier A, et al. Magnetic resonance imaging of the axial skeleton for detecting bone metastases in patients with high-risk prostate cancer: diagnostic and cost-effectiveness and comparison with current detection strategies. J Clin Oncol 2007, 25:3281-3287.
83. Antoch G, Vogt FM, Freudenberg LS, et al. Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA 2003, 290:3199-3206.
84. Ketelsen D, Rothke M, Aschoff P, et al. Detection of bone metastasis of prostate cancer-comparison of whole-body MRI and bone scintigraphy. Rofo 2008, 180:746-752. (in German).
85. Eschmann SM, Pfannenberg AC, Rieger A, et al. Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer. Nuklearmedizin 2007, 46:161-168.
86. Nakanishi K, Kobayashi M, Nakaguchi K, et al. Whole-body MRI for detecting metastatic bone tumor: diagnostic value of diffusion-weighted images. Magn Reson Med Sci 2007, 6:147-155.
87. Luboldt W, Kufer R, Blumstein N, et al. Prostate carcinoma: diffusion-weighted imaging as potential alternative to conventional MR and 11C-choline PET/CT for detection of bone metastases. Radiology 2008, 249:1017-1025.